Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 23, 2023

BUY
$133.59 - $154.65 $2,671 - $3,093
20 Added 0.71%
2,852 $425,000
Q2 2023

Aug 14, 2023

SELL
$132.51 - $164.9 $3,047 - $3,792
-23 Reduced 0.81%
2,832 $381,000
Q1 2023

May 12, 2023

BUY
$144.61 - $166.54 $3,470 - $3,996
24 Added 0.85%
2,855 $455,000
Q4 2022

Feb 09, 2023

SELL
$138.31 - $165.87 $13,831 - $16,587
-100 Reduced 3.41%
2,831 $457,000
Q3 2022

Nov 07, 2022

BUY
$134.21 - $153.93 $8,186 - $9,389
61 Added 2.13%
2,931 $394,000
Q2 2022

Aug 05, 2022

BUY
$137.62 - $174.96 $11,147 - $14,171
81 Added 2.9%
2,870 $439,000
Q1 2022

May 04, 2022

SELL
$131.98 - $163.75 $2,639 - $3,275
-20 Reduced 0.71%
2,789 $452,000
Q4 2021

Jan 25, 2022

SELL
$107.43 - $135.93 $3,867 - $4,893
-36 Reduced 1.27%
2,809 $380,000
Q3 2021

Oct 27, 2021

BUY
$106.4 - $120.78 $2,660 - $3,019
25 Added 0.89%
2,845 $307,000
Q2 2021

Aug 04, 2021

SELL
$105.21 - $117.21 $631 - $703
-6 Reduced 0.21%
2,820 $318,000
Q1 2021

May 07, 2021

BUY
$102.3 - $112.62 $42,659 - $46,962
417 Added 17.31%
2,826 $306,000
Q4 2020

Feb 10, 2021

BUY
$80.49 - $108.67 $193,900 - $261,786
2,409 New
2,409 $258,000
Q3 2020

Oct 29, 2020

SELL
$85.91 - $100.83 $192,610 - $226,060
-2,242 Closed
0 $0
Q2 2020

Jul 23, 2020

BUY
$73.37 - $98.18 $164,495 - $220,119
2,242 New
2,242 $220,000
Q1 2018

May 08, 2018

SELL
$92.01 - $123.21 $198,833 - $266,256
-2,161 Closed
0 $0
Q4 2017

Jan 12, 2018

BUY
$89.56 - $98.21 $193,539 - $212,231
2,161
2,161 $209,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Trellis Advisors, LLC Portfolio

Follow Trellis Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trellis Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Trellis Advisors, LLC with notifications on news.